Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Diarrhea Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Diarrhea Overview | 13 | 1 |
| Pipeline Products for Diarrhea Comparative Analysis | 14 | 1 |
| Diarrhea Therapeutics under Development by Companies | 15 | 2 |
| Diarrhea Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Diarrhea Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Diarrhea Products under Development by Companies | 21 | 3 |
| Diarrhea Products under Investigation by Universities/Institutes | 24 | 1 |
| Diarrhea Companies Involved in Therapeutics Development | 25 | 31 |
| A. Menarini Industrie Farmaceutiche Riunite Srl | 25 | 1 |
| Ache Laboratorios Farmaceuticos S/A | 26 | 1 |
| Actelion Ltd | 27 | 1 |
| Aegis Therapeutics, LLC | 28 | 1 |
| AlbireoPharma | 29 | 1 |
| Allergan Plc | 30 | 1 |
| Anatara Lifesciences Limited | 31 | 1 |
| Ardelyx, Inc. | 32 | 1 |
| Assembly Biosciences, Inc. | 33 | 1 |
| Codagenix, Inc. | 34 | 1 |
| Cosmo Pharmaceuticals S.p.A | 35 | 1 |
| DesignMedix, Inc. | 36 | 1 |
| DiscoveryBiomed, Inc. | 37 | 1 |
| Genextra S.p.a. | 38 | 1 |
| GlaxoSmithKline Plc | 39 | 1 |
| GP Pharm, S.A. | 40 | 1 |
| Mucosis B.V. | 41 | 1 |
| Nippon Shinyaku Co., Ltd. | 42 | 1 |
| Novartis AG | 43 | 1 |
| Pfizer Inc. | 44 | 1 |
| Prokarium Limited | 45 | 1 |
| Protagonist Therapeutics Inc. | 46 | 1 |
| Rebiotix Inc. | 47 | 1 |
| Recce Pty Ltd | 48 | 1 |
| RxBio, Inc. | 49 | 1 |
| Scandinavian Biopharma Holding AB | 50 | 1 |
| Sigmoid Pharma Limited | 51 | 1 |
| Summit Therapeutics Plc | 52 | 1 |
| Synthetic Biologics, Inc. | 53 | 1 |
| Syntiron LLC | 54 | 1 |
| Tasly Pharmaceutical Group Co., Ltd. | 55 | 1 |
| Diarrhea Therapeutics Assessment | 56 | 11 |
| Assessment by Monotherapy Products | 56 | 1 |
| Assessment by Target | 57 | 3 |
| Assessment by Mechanism of Action | 60 | 3 |
| Assessment by Route of Administration | 63 | 2 |
| Assessment by Molecule Type | 65 | 2 |
| Drug Profiles | 67 | 83 |
| ABM-101 Drug Profile | 67 | 1 |
| ACH-04 Drug Profile | 68 | 1 |
| ASP-7147 Drug Profile | 69 | 1 |
| cadazolid Drug Profile | 70 | 2 |
| Campylobacter jejuni [strain CPS81-176] vaccine Drug Profile | 72 | 2 |
| cholestyramine Drug Profile | 74 | 1 |
| Clostridium difficile vaccine Drug Profile | 75 | 1 |
| crofelemer DR Drug Profile | 76 | 3 |
| Drug for Diarrhea Drug Profile | 79 | 1 |
| eluxadoline Drug Profile | 80 | 4 |
| Escherichia coli vaccine Drug Profile | 84 | 1 |
| ETEC vaccine Drug Profile | 85 | 1 |
| ETEC vaccine Drug Profile | 86 | 1 |
| Etvax Drug Profile | 87 | 2 |
| GVXNSD-133 Drug Profile | 89 | 1 |
| GXG-8 Drug Profile | 90 | 1 |
| ibodutant Drug Profile | 91 | 1 |
| IMSUTMR-1501 Drug Profile | 92 | 1 |
| infectious diarrhea [serotype H11] vaccine Drug Profile | 93 | 1 |
| LJN-452 Drug Profile | 94 | 1 |
| obeticholic acid Drug Profile | 95 | 11 |
| octreotide acetate Drug Profile | 106 | 1 |
| octreotide acetate MAR Drug Profile | 107 | 1 |
| Peptide to Activate NHE-3 for Diarrhea Drug Profile | 108 | 1 |
| PF-06425090 Drug Profile | 109 | 2 |
| prulifloxacin Drug Profile | 111 | 2 |
| PZ-7475 Drug Profile | 113 | 1 |
| RBX-2660 Drug Profile | 114 | 3 |
| RDX-98940 Drug Profile | 117 | 1 |
| RECCE-355 Drug Profile | 118 | 1 |
| Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea Drug Profile | 119 | 1 |
| Recombinant Proteins for Infectious Diarrhea Drug Profile | 120 | 1 |
| ribaxamase Drug Profile | 121 | 5 |
| ridinilazole Drug Profile | 126 | 5 |
| rifamycin CR Drug Profile | 131 | 2 |
| Rx-100 Drug Profile | 133 | 2 |
| Small Molecule to Block CFTR for Diarrhoea Drug Profile | 135 | 1 |
| Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease Drug Profile | 136 | 1 |
| Small Molecules for Microbial Infections Drug Profile | 137 | 1 |
| Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea Drug Profile | 138 | 1 |
| Small Molecules to Inhibit CFTR for Secretory Diarrhea Drug Profile | 139 | 1 |
| SYN-006 Drug Profile | 140 | 1 |
| SYN-007 Drug Profile | 141 | 1 |
| Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea Drug Profile | 142 | 1 |
| Typhetec Drug Profile | 143 | 1 |
| Vaccine 1 for Diarrhea Drug Profile | 144 | 1 |
| Vaccine 2 for Diarrhea Drug Profile | 145 | 1 |
| Vaccine for Traveler's Diarrhea Drug Profile | 146 | 1 |
| Vaccine for Traveler's Diarrhea Drug Profile | 147 | 1 |
| Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea Drug Profile | 148 | 1 |
| Yersinia pestis vaccine Drug Profile | 149 | 1 |
| Diarrhea Dormant Projects | 150 | 3 |
| Diarrhea Discontinued Products | 153 | 1 |
| Diarrhea Product Development Milestones | 154 | 9 |
| Featured News &Press Releases | 154 | 1 |
| Jul 07, 2016: Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004 | 154 | 1 |
| Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX | 155 | 1 |
| May 16, 2016: Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea | 155 | 1 |
| Mar 07, 2016: Napo and Salix Settle Litigation | 156 | 1 |
| Mar 01, 2016: Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea | 157 | 1 |
| Dec 14, 2015: Allergan Announces U.S. Availability of VIBERZI (eluxadoline) for Treatment of Irritable Bowel Syndrome with Diarrhea in Adults | 157 | 1 |
| Dec 07, 2015: Synthetic Biologics to Webcast on SYN-004 at Microbiome Clinical Program Seminar | 158 | 1 |
| Nov 19, 2015: Synthetic Biologics to Host Microbiome Clinical Program Seminar on SYN-004 in New York City | 158 | 1 |
| Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix | 158 | 1 |
| May 06, 2014: Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week | 159 | 1 |
| Feb 27, 2014: Actelion's Novel Antibiotic Cadazolid Receives US FDA Qualified Infectious Disease Product Designation For The Treatment Of Clostridium Difficile-Associated Diarrhea | 160 | 1 |
| Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation | 161 | 1 |
| Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy | 161 | 2 |
| Appendix | 163 | 2 |
| Methodology | 163 | 1 |
| Coverage | 163 | 1 |
| Secondary Research | 163 | 1 |
| Primary Research | 163 | 1 |
| Expert Panel Validation | 163 | 1 |
| Contact Us | 163 | 1 |
| Disclaimer | 164 | 1 |